SCHEMBL759109

SCHEMBL759109

Clc1ccc(-c2ccccc2)c(CCBr)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 3/20 0.46
FFAR4 Q5NUL3 3/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.40
CYP1A2 P05177 1/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
CSNK2A1 P68400 2/20 0.39
CYP3A4 P08684 1/20 0.39
ALOX15 P16050 1/20 0.39
HIF1A Q16665 1/20 0.39
RXFP1 Q9HBX9 1/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31464099 1.00 FFAR1 (0.46) FFAR1FFAR4PTGDR2CYP1A2KMT2A
SCHEMBL1113833 0.85 FFAR1 (0.45) FFAR1FFAR4PTGDR2CYP1A2KMT2A
SCHEMBL3746249 0.84 FFAR1 (0.50) FFAR1FFAR4PTGDR2CYP1A2KMT2A
SCHEMBL27718714 0.79 FFAR1 (0.46) FFAR1FFAR4PTGDR2CYP1A2KMT2A
SCHEMBL14686251 0.79 FFAR1 (0.49) FFAR1FFAR4PTGDR2CYP1A2KMT2A
SCHEMBL28238287 0.79 ADORA3 (0.45) FFAR1FFAR4PTGDR2KMT2AMEN1
SCHEMBL3746360 0.78 FFAR4 (0.66) FFAR1FFAR4PTGDR2
SCHEMBL3732787 0.78 FFAR1 (0.43) FFAR1FFAR4PTGDR2CYP1A2KMT2A
SCHEMBL11287161 0.78 CYP2C19 (0.45) FFAR1FFAR4PTGDR2CYP1A2HSD17B10
SCHEMBL27417857 0.78 FFAR1 (0.48) FFAR1FFAR4PTGDR2CYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326744-A1 PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FUJIFILM CORPORATION (JP) 2025-10-23 US disclosed
WO-2024043334-A1 NOVEL PIPERAZINE DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION 富士フイルム株式会社 2024-02-29 WO disclosed
CN-101535280-B Arylsulfonamide compounds GENENTECH INC 2012-06-27 CN disclosed
EP-1670766-B1 Bicyclic imino acid derivatives for the treatment of (inter alia) diseases relating to the locomotor system SANOFI AVENTIS DEUTSCHLAND (DE) 2012-03-21 EP disclosed
CN-102105449-A Arylsulfonamide compounds, compositions and methods of use GENENTECH INC 2011-06-22 CN disclosed
US-7829721-B2 Specific caspase-10 inhibitors MERCK PATENT GMBH (DE) 2010-11-09 US disclosed
CN-101535280-A Arylsulfonamide compounds GENENTECH INC (US) 2009-09-16 CN disclosed
US-20080255173-A1 Novel Specific Caspase-10 Inhibitors MERCK PATENT GESELLSCHAFT (DE) 2008-10-16 US disclosed
EP-1817031-A1 NOVEL SPECIFIC CASPASE-10 INHIBITORS Merck Patent GmbH (DE) 2007-08-15 EP disclosed
EP-1763516-A2 SUBSTITUTED TETRAHYDROISOCHINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRAGS Sanofi-Aventis Deutschland GmbH (DE) 2007-03-21 EP disclosed
EP-1670766-A1 BICYCLIC IMINO ACID DERIVATIVES USED AS INHIBITORS OF MATRIX-METALLOPROTEINASES Sanofi-Aventis Deutschland GmbH (DE) 2006-06-21 EP disclosed
WO-2006058592-A1 NOVEL SPECIFIC CASPASE-10 INHIBITORS MERCK PATENT GMBH (DE) 2006-06-08 WO disclosed
WO-2006002763-A2 SUBSTITUTED TETRAHYDROISOCHINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRAGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2006-01-12 WO disclosed
WO-2005030728-A1 BICYCLIC IMINO ACID DERIVATIVES USED AS INHIBITORS OF MATRIX-METALLOPROTEINASES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255173-A1 Novel Specific Caspase-10 Inhibitors CASP10, CASP1, CASP5 FFAR1 624/4885FFAR4 860/4885PTGDR2 3995/4885
US-20250326744-A1 PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION ABCB11, ABCC1, SLC11A2 FFAR1 3148/4885FFAR4 4300/4885PTGDR2 2704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.